fda compounding glp-1 enforcement news New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA cracks down on 'misleading'

Not intended for medical, therapeutic, or diagnostic purposes.

CJC-1295 and Infertility Research from the early 1990s suggests that CJC-1295 and other GRF analogues may be useful in promoting ovulation in infertile female patients

Why claims data alone cant explain real-world GLP-1 outcomes As adoption accelerates, pharmaceutical companies are racing to innovate through new formulations, delivery options, and combination approaches that improve tolerability and long-term outcomes

This selectivity makes Ipamorelin one of the cleanest and most side-effect-free peptides available

Noom and Second Nature are online and app-based programs, whereas Weight Watchers has an optional face-to-face meeting plan